Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation

被引:22
|
作者
Qian, Guoqing [1 ]
Wang, Dongsheng [1 ]
Magliocca, Kelly R. [2 ]
Hu, Zhongliang [1 ,3 ]
Nannapaneni, Sreenivas [1 ]
Kim, Sungjin [4 ]
Chen, Zhengjia [5 ]
Sun, Shi-Yong [1 ]
Shin, Dong M. [1 ]
Saba, Nabil F. [1 ]
Chen, Zhuo G. [1 ]
机构
[1] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA
[3] Cent S Univ, Xiangya Sch Med, Dept Pathol, Changsha 410078, Hunan, Peoples R China
[4] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[5] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA
基金
美国国家卫生研究院;
关键词
Human papillomavirus; c-Met; p53; Head and neck cancer; SQUAMOUS-CELL CARCINOMA; RECEPTOR TYROSINE KINASE; WILD-TYPE P53; HEPATOCYTE GROWTH-FACTOR; BREAST-CANCER CELLS; OROPHARYNGEAL CANCER; THERAPEUTIC TARGET; CLINICAL-TRIALS; HEAD; NECK;
D O I
10.1016/j.ejca.2016.06.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) carries a distinct clinical behaviour. c-Met oncogene is an important driver for tumour progression and its relationship with HPV in OPSCC was explored in the present study. Experimental design: Knockdown of HPV oncogene E6 or p53 alone and in combination was performed to examine their effects on c-Met expression by Western blot and quantitative realtime polymerase chain reaction. The effects of c-Met inhibition on cell proliferation, migration, and colony formation were examined in HPV-positive head and neck squamous cell carcinoma (HNSCC) cells. Retrospectively collected OPSCC patient specimens (N = 78) were stained for c-Met by immunohistochemistry and the staining levels were correlated with HPV status and patient outcomes. Results: E6 knockdown decreased c-Met protein and mRNA expression in HPV-positive HNSCC cells, which was partially abolished by the elimination of p53. Reducing c-Met decreased cell proliferation, migration, and colony formation in HPV-positive HNSCC cells. In OPSCC patient samples, high c-Met expression was associated with HPV-positive status (OR = 4.11, 95%CI: 1.16-14.55, P = 0.028) and tumour stage (OR = 0.27, 95%CI: 0.08 -0.93, P = 0.039) by multivariable analysis. In T3/T4 stage patients, high c-Met expression was associated with HPV positivity and low p53 levels, supporting an axis of E6-p53-c-Met regulation. Furthermore, high c-Met expression was marginally associated with poor disease-free survival in HPV-positive patients. Conclusions: Our results suggest that c-Met may serve as a novel target for treating HPV-associated OPSCC. The data also demonstrate that HPV E6 upregulates c-Met expression partially through p53 downregulation. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:21 / 32
页数:12
相关论文
共 50 条
  • [21] Human papillomavirus 18 E6 inhibits phosphorylation of p53 expressed in HeLa cells
    Amrendra K Ajay
    Avtar S Meena
    Manoj K Bhat
    Cell & Bioscience, 2
  • [22] DEGRADATION OF P53 ONLY IS NOT SUFFICIENT FOR THE GROWTH-STIMULATORY EFFECT OF HUMAN PAPILLOMAVIRUS-16 E6 ONCOPROTEIN IN HUMAN EMBRYONIC FIBROBLASTS
    ISHIWATARI, H
    HAYASAKA, N
    INOUE, H
    YUTSUDO, M
    HAKURA, A
    JOURNAL OF MEDICAL VIROLOGY, 1994, 44 (03) : 243 - 249
  • [23] P53 protein represses the E6 promoter activity of human papillomavirus type 59
    Rho, J
    Kim, DW
    Choe, J
    MOLECULES AND CELLS, 1996, 6 (03) : 359 - 365
  • [24] A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells
    Messa, Lorenzo
    Celegato, Marta
    Bertagnin, Chiara
    Mercorelli, Beatrice
    Nannetti, Giulio
    Palu, Giorgio
    Loregian, Arianna
    SCIENTIFIC REPORTS, 2018, 8
  • [25] A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells
    Lorenzo Messa
    Marta Celegato
    Chiara Bertagnin
    Beatrice Mercorelli
    Giulio Nannetti
    Giorgio Palù
    Arianna Loregian
    Scientific Reports, 8
  • [26] Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53
    Cooper, B
    Schneider, S
    Bohl, J
    Jiang, YH
    Beaudet, A
    Vande Pol, S
    VIROLOGY, 2003, 306 (01) : 87 - 99
  • [27] The E6 oncoprotein of human papillomavirus 16 as a therapeutic target
    Dymalla, Susanne
    Butz, Karin
    Lohrey, Claudia
    Scheffner, Martin
    Sehr, Peter
    Lewis, Joe
    Hoppe-Seyler, Felix
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3606S - 3606S
  • [28] PKN binds and phosphorylates human papillomavirus E6 oncoprotein
    Gao, QS
    Kumar, A
    Srinivasan, S
    Singh, L
    Mukai, H
    Ono, Y
    Wazer, DE
    Band, V
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (20) : 14824 - 14830
  • [29] TARGETING AND DEGRADATION OF P53 BY E6 OF HUMAN PAPILLOMAVIRUS TYPE-16 IS PREFERENTIAL FOR THE 1620+ P53 CONFORMATION
    MEDCALF, EA
    MILNER, J
    ONCOGENE, 1993, 8 (10) : 2847 - 2851
  • [30] The ING4 Binding with p53 and Induced p53 Acetylation were Attenuated by Human Papillomavirus 16 E6
    Guo, Yi
    Meng, Xiangkai
    Wang, Qian
    Wang, Yanan
    Shang, Hong
    PLOS ONE, 2013, 8 (08):